Evidence map›Paper›PMID 41725640›Full record

ArticleAdvances in radiation oncology2026

Esophageal Cancer Cells Exhibit Heterogeneity in DNA Double-Strand Break Repair and G2/M Checkpoint Arrest Associated With Cell Viability After Ionizing Radiation.

Kohei Tateno, Ken Okuda, Shunji Haruna, Mayu Isono, Takaaki Ishikawa, Hikaru Okumura, Ryota Hayashi, Ryuta Suzuki, Takumi Takahashi, Tamaki Saito and 7 more

Abstract read
In one paragraph

Article in Advances in radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Kohei TatenoDivision of Molecular Oncological Pharmacy, Faculty of Pharmacy, Keio University, Shibakoen, Minato-ku, Tokyo, Japan.
Ken OkudaDivision of Molecular Oncological Pharmacy, Faculty of Pharmacy, Keio University, Shibakoen, Minato-ku, Tokyo, Japan.
Shunji HarunaDivision of Molecular Oncological Pharmacy, Faculty of Pharmacy, Keio University, Shibakoen, Minato-ku, Tokyo, Japan.
Mayu IsonoDivision of Molecular Oncological Pharmacy, Faculty of Pharmacy, Keio University, Shibakoen, Minato-ku, Tokyo, Japan.
Takaaki IshikawaDivision of Molecular Oncological Pharmacy, Faculty of Pharmacy, Keio University, Shibakoen, Minato-ku, Tokyo, Japan.
Hikaru OkumuraDivision of Molecular Oncological Pharmacy, Faculty of Pharmacy, Keio University, Shibakoen, Minato-ku, Tokyo, Japan.
Ryota HayashiDivision of Molecular Oncological Pharmacy, Faculty of Pharmacy, Keio University, Shibakoen, Minato-ku, Tokyo, Japan.
Ryuta SuzukiDivision of Molecular Oncological Pharmacy, Faculty of Pharmacy, Keio University, Shibakoen, Minato-ku, Tokyo, Japan.
Takumi TakahashiDivision of Molecular Oncological Pharmacy, Faculty of Pharmacy, Keio University, Shibakoen, Minato-ku, Tokyo, Japan.
Tamaki SaitoDivision of Molecular Oncological Pharmacy, Faculty of Pharmacy, Keio University, Shibakoen, Minato-ku, Tokyo, Japan.
Takehiko YokoboriDivision of Gene Therapy Science, Gunma University, Initiative for Advanced Research, Showa-machi, Maebashi, Japan.
Yuki UchiharaDivision of Molecular Oncological Pharmacy, Faculty of Pharmacy, Keio University, Shibakoen, Minato-ku, Tokyo, Japan.
Keiji SuzukiDepartment of Radiation Medical Sciences, Nagasaki University Atomic Bomb Disease Institute, Sakamoto, Nagasaki, Japan.
Motohiro YamauchiHospital Campus Laboratory, Radioisotope Center, Central Institute of Radioisotope Science and Safety Management, Kyushu University, Fukuoka, Japan.
Ken ShirabeDepartment of General Surgical Science, Graduate School of Medicine, Gunma University, Showa-machi, Maebashi, Japan.
Hiroshi SaekiDepartment of General Surgical Science, Graduate School of Medicine, Gunma University, Showa-machi, Maebashi, Japan.
Atsushi ShibataDivision of Molecular Oncological Pharmacy, Faculty of Pharmacy, Keio University, Shibakoen, Minato-ku, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Esophageal cancer lacks characteristic mutations in DNA repair genes; therefore, DNA damage response (DDR) factors have not been widely explored as predictive biomarkers in esophageal cancer. In this study, we explored the potential heterogeneity of DDR capabilities following exposure to ionizing radiation (IR). Methods and Materials: DNA repair protein RAD51 homolog 1/Rad51 recombinase (RAD51), breast cancer susceptibility gene 1, and replication protein A foci formation were analyzed in 15 esophageal cancer cell lines after IR. DNA damage signaling, including phosphorylation of ataxia telangiectasia mutation, Chk2, and Chk1, was examined by immunoblotting. G2/M checkpoint arrest after IR was assessed by scoring mitotic cells. The mode of cell death and cell viability after IR were evaluated using immunofluorescence staining and colony formation assay. Results: Notably, we found significant variations in RAD51 foci formation among 15 esophageal cancer cell lines. Analyzing 2 cell lines, with the highest and lowest RAD51 foci formation each, revealed that cells with low RAD51 foci formation (DDR-defective cell lines) exhibited impaired double-strand break (DSB) end resection, and reduced ataxia telangiectasia mutation-Chk2 and ATR-Chk1 signaling. The DDR-defective cell lines showed increased mitosis with DSBs and enhanced radiosensitivity. Conversely, DDR-proficient cell lines that exhibited intact G2/M checkpoint arrest become significantly more radiosensitive when treated with ATR or WEE1 inhibitors, which abrogate G2/M checkpoint arrest and increase mitosis with DSBs. Conclusions: Esophageal cancer cell lines with lower capability of RAD51 foci formation exhibited defective DDR and G2/M checkpoint arrest associated with higher radiosensitivity. These findings suggest novel possibilities for predicting the efficacy of DNA damage-inducing cancer therapies, such as chemoradiotherapy, based on DDR proficiency, potentially guiding personalized treatment strategies for esophageal cancer.

Identifiers

PMID41725640
PMCPMC12924126

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.